Biofrontera achieves milestones on Series B-3 warrants, unlocking $8M gross proceeds

Biofrontera Inc.

Board certified >5% YoY revenue growth (Jan-Apr 2024 vs 2023, ex-related parties) and >95% CRM adoption.
Warrant exercise triggers $8M gross proceeds to Biofrontera.
Shareholders approved authorized share increase from 15M to 35M at April 24 special meeting.
Warrants expiration now 5 days after S-1 effectiveness (filed May 2) or Feb 22, 2027.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.